Literature DB >> 3419862

Treatment with cisapride of the gastrointestinal and urological sequelae of spinal cord transection: case report.

M Etienne1, M Verlinden, A Brassinne.   

Abstract

We describe the case of a paraplegic patient who suffered traumatic spinal cord injury at the level of the twelfth thoracic vertebra. Within a short period of time following the injury, urinary (neuropathic bladder) and gastrointestinal (atomic colon) sequelae arose. Treatment with Cisapride (R 51 619, Janssen Pharmaceutica) was undertaken in an attempt to increase colonic motility and to reduce urinary retention. These goals were reached rapidly with a dose of 10 mg q.i.d.; the effect has been maintained for at least 18 months since starting the therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3419862     DOI: 10.1038/sc.1988.26

Source DB:  PubMed          Journal:  Paraplegia        ISSN: 0031-1758


  4 in total

1.  Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

Authors:  B Darblade; D Behr-Roussel; D Gorny; T Lebret; G Benoit; J-P Hieble; D Brooks; L Alexandre; F Giuliano
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

2.  Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.

Authors:  S M Candura; E Messori; G P Franceschetti; G D'Agostino; D Vicini; M Tagliani; M Tonini
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 3.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 4.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.